| X-linked agammaglobulinemia

Cutaquig vs Gamunex - C

Side-by-side clinical, coverage, and cost comparison for x-linked agammaglobulinemia.

Deep comparison between: Cutaquig vs Gamunex-C with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGamunex-C has a higher rate of injection site reactions vs Cutaquig based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Gamunex-C but not Cutaquig, including UnitedHealthcare

Category

Cutaquig

Gamunex-C

At A Glance

RouteSC injection

FrequencyWeekly

ClassImmune globulin (IGSC)

RouteIV infusion / SC injection

FrequencyEvery 3-4 weeks

ClassImmune globulin

Indications

Primary immune deficiency disorder
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Congenital agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency
Congenital agammaglobulinemia
Immune thrombocytopenic purpura
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Dosing

Primary immune deficiency disorder, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC dose based on pharmacokinetic and clinical response; for patients switching from IGIV, calculate initial weekly dose by dividing monthly IGIV dose by weeks between infusions and multiplying by adjustment factor of 1.30; for patients switching from IGSC, maintain same weekly dose; dosing interval from daily up to every other week.

Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.

Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).

Contraindications

Previous anaphylactic or severe systemic reaction to subcutaneous administration of human immune globulin or to any component of CUTAQUIG, including Polysorbate 80
IgA deficiency with antibodies against IgA and history of hypersensitivity to human globulin treatment

Previous anaphylactic or severe systemic reaction to human immune globulin
IgA deficiency with antibodies against IgA and history of hypersensitivity reaction

Drug Interactions

162View drug interactions

Adverse Reactions

Most common (>=5%) Local infusion site reactions (redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, cough

Postmarketing Pancytopenia, leukopenia, hemolytic anemia, anaphylactic reaction, hypersensitivity reaction, angioneurotic edema, thromboembolism, Stevens-Johnson syndrome, aseptic meningitis, seizures, cardiac arrest, respiratory failure, pulmonary embolism, acute renal failure, dizziness, nausea, pruritus, fatigue

Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.

Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.

Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.

Pharmacology

Immune globulin replacement; CUTAQUIG supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, with IgG subclass distribution closely proportional to native human plasma, restoring abnormally low IgG levels to the normal range to help prevent infections in primary humoral immunodeficiency.

GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cutaquig